NTLA Q1 2019 Earnings — Intellia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

NTLAIntellia Therapeutics, Inc.

$2B

Q1 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$10M+39.7% YoY

Gross Profit

-$13M-127.3% margin

Operating Income

-$24M-228.2% margin

Net Income

-$22M-210.3% margin

EPS (Diluted)

$-0.49

QoQ Revenue Growth

+32.4%

Cash Flow

Operating Cash Flow

-$21M

Free Cash Flow

-$23M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$344M

Total Liabilities

$80M

Stockholders' Equity

$264M

Cash & Equivalents

$47M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$10M	$7M	+39.7%
Gross Profit	-$13M	-$15M	+11.6%
Operating Income	-$24M	-$22M	-6.1%
Net Income	-$22M	-$21M	-2.7%